 |
|
January Co-op Feature
100% Claims Auditing
_________________________
Aggressive contract negotiation is critically important, but it's only half the battle. Plans also need to be certain their contract terms are met. Did you know National CooperativeRx audits one hundred percent of claims for financial accuracy? Find out more about how we protect our plans and why it is so critical to their bottom line. |
|
|
_________________________
Upcoming Events featuring
National CooperativeRx |
|
|
|
Health Benefits Conference and Expo
January 31 to February 1, 2011
Sheraton Sand Key Resort, Clearwater Beach, FL
NAHU Capitol Conference
February 14 to 16, 2011
Hyatt Regency
Washington, D.C.
Learn more ________________________ |
|
 |
| National CooperativeRx is a not-for-profit coalition founded and owned by plan sponsors to achieve higher value prescription benefits through volume purchasing, clinical solutions, actionable data and unparalleled customer service. For your sales and marketing needs, please contact us at info@wisrx.com or by phone at 866-679-9479, ext. 223. |
|
|
|
National CooperativeRx 2011: What's in Store
Introducing Pharmacy Advisor
WisconsinRx/National CooperativeRx is pleased to introduce Pharmacy Advisor, a new clinical program from CVS Caremark that we are bringing to our members at no cost in 2011.
Pharmacy Advisor targets chronic disease, which is the biggest cost driver in medicine today. The program will focus on diabetes initially and will add other disease categories in the future.
Pharmacy Advisor works by identifying gaps in care and non-adherence issues within our population, and then provides highly targeted counseling and support to enrollees in whatever method is most effective for them, whether that be face-to-face discussions with a pharmacist, live inbound calls, live outbound calls, mailings or automated phone reminders.
WisconsinRx/National Cooperative has advice for member plans that want to make the most of Pharmacy Advisor. Please contact us for more information, or visit our Pharmacy Advisor webpage. |
|
Associated Press. Consumers who get their DNA tested for health risks take the results in stride, says the first major study of how people react to genetic testing. But getting that assessment for diseases didn't inspire customers to eat better or exercise more, researchers found. (Ritter, 1/12) Full story
|
|
Health Day. Amid the ongoing controversy over routine antibiotic use for children with acute ear infections, two new studies support the practice when stringent diagnostic criteria are met. (Salamon, 1/12) Full story
|
|
Daily Finance. Unknown to most Americans, the country is now in the grips of a life-threatening drug shortage, and medical professionals are extremely concerned. (Alazraki, 1/11) Full story
|
|
Health Day. Common painkillers taken to treat inflammation, such as Celebrex and Advil, can raise the risk of heart attack, stroke or death, a review of existing research suggests. (Reinberg, 1/11) Full story
|
|
Wall Street Journal. Some health advocacy groups that say they are speaking for patients' interests before legislatures, regulatory agencies or public forums fail to disclose their funding from drug makers, a new study from Columbia University says. (Wilson, 1/13). Full Story
|
|
Sacramento Bee. The newly elected California Attorney General has asked the U.S. Supreme Court to end "pay-for-delay" agreements that protect name-brand drugs such as Cipro - an antibiotic used to treat exposure to anthrax - against competition from cheaper generic drugs. (Calvan, 1/8). Full Story
|
|
Associated Press. Makers of generic biotech drugs are waging an eleventh-hour battle to reduce the competitive protection that the emerging health overhaul bill would give to brand-name producers of the expensive pharmaceuticals. (Fram, 1/14) Full Story
|
|
New York Times. The FDA announced Thursday that it would sharply restrict some of the nation's most popular prescription painkillers, saying they cause many patients to poison themselves with overdoses of the drug acetaminophen. (Harris, 1/13) Full Story
|
|
New York Times. The Obama administration, following a lengthy internal debate, has unexpectedly come down on the side of pharmaceutical companies that are accused of overcharging public hospitals and clinics that care for large numbers of poor people. (Pear, 1/9) Full story
|
|
 |
|
